Sosei Heptares to Utilize its Structure-Based Drug Design Expertise in New COVID-19 R&D Program

Shots:

• The company will apply its unique structure-based drug design platform and capabilities to the global research efforts to discover drugs targeting COVID-19
• Sosei Heptares has initiated a new R&D program to identify compounds blocking the activity of SARS-CoV-2 MPro protease (Nsp5), which has been designated as a potential target for drug development
• The company is looking for a collaboration with other partners to support the program and all the finding will be freely accessible to the global research community looking for the treatments of COVID-19

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: News Scientist